関節リウマチ治療薬の創薬

Abstract

The value of the rheumatoid arthritis (RA) market currently stands at approximately US$11.6 billion and is continuing to grow, driven mainly by the biologic DMARDs. It is dominated by five major pharma companies: Abbott, Amgen, Johnson & Johnson, Schering-Plough and Wyeth, which between them market three of the most successful biologics, the tumour necrosis factor inhibitors Enbrel (etanercept), Remicade (infliximab) and Humira (adalimumab).

Research into new treatments is intense, driven by the need for safer and even more effective medications with more convenient dosing schedules. GlaxoSmithKline, Johnson & Johnson, Roche, Schering-Plough and UCB all have biologics in the late phases of development, while Pfizer is pinning its hopes on its oral kinase inhibitors, which are currently in Phase II development. As these new therapies come on board and the market becomes more competitive, the prospects for RA patients can only improve.

This report provides a complete assessment of the market' s potential

This new management report provides a complete examination of the RA market and its prospects in the medium term. Packed with analysis and forecasts, anyone needing to understand the drivers of this fast growing sector need look no further.

Providing…

• Detailed assessment and 5-year forecasts for current leading products by value
• A detailed review and assessment of up and coming products
• Unique product assessment and scoring

Major approaches

• Adenosine receptor antagonist
• B-cell targeted therapy
• Cathepsin-S inhibitors
• Chemokine receptor antagonists
• DHODH inhibitors
• Glucocorticoids
• Interleukin inhibitors
• Kinase inhibitors
• Lymphotoxin beta and light pathway inhibitor
• Non-steroidal anti-inflammatory drugs
• RANK ligand inhibitor
• T-cell co-stimulation modulator
• TNF inhibitors
• Traditional disease-modifying anti-rheumatic drugs

Table of Contents

• INTRODUCTION
• WHAT IS RHEUMATOID ARTHRITIS?
  • Pathogenesis Of Rheumatoid Arthritis
  • Classification Of Rheumatoid Arthritis
  • Assessment Of Disease Activity And Response To Treatment
• CURRENT TREATMENT OPTIONS
  • Diagnosis of Rheumatoid Arthritis
  • Pharmacological Therapy
  • Treatment Strategies
• PATIENT STATISTICS
  • Incidence and Prevalence
  • The Future
• THE RHEUMATOID ARTHRITIS MARKET
  • PLAYERS AND PRODUCTS
    • Players And Products In 2007
    • Players And Products In 2015
  • DRUG GROWTH DRIVERS AND DAMPENERS
• ANALYSIS OF CURRENT LEADING PRODUCTS
  • NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
    • Celebrex
    • Arcoxia
    • Mobic
  • GLUCOCORTICOIDS
  • TRADITIONAL DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS
  • BIOLOGICAL AGENTS
    • TNF Inhibitors
      • Remicade
      • Humira
      • Enbrel
    • Interleukin-1 Receptor Inhibitor
      • Kineret
    • B-Cell Targeted Therapy
      • Rituxan/MabThera
    • T-Cell Co-Stimulation Modulator
      • Orencia
• RESEARCH AND DEVELOPMENT OF RHEUMATOID ARTHRITIS DRUGS
  • LATE-PHASE PROJECTS
    • TNF Inhibitors
      • Cimzia
      • Golimumab
    • Interleukin-6 Receptor Inhibitor
      • Actemra
    • Interleukin-1 Receptor Inhibitor
      • Canakinumab
    • B-Cell Targeted Therapy
      • Ocrelizumab
      • Ofatumumab
    • Non-Steroidal Anti-Inflammatory Drugs
      • Iguratimod
      • PN-400
    • Glucocorticoid
      • Lodotra
  • PHASE II PROJECTS
  • Oral Therapies
    • Adenosine Receptor Antagonist
      • CF101
    • Cathepsin-S Inhibitor
      • RWJ-445380
    • Chemokine Receptor Antagonists
      • Selzentry
    • DHODH Inhibitor
      • SC12267
    • Interleukin Inhibitors
      • Apilimod
    • Kinase Inhibitors
      • 681323
      • 856553
      • BMS-582949
      • CP-195543
      • CP-690550
      • INCB18424
      • PH-797804
      • SCIO-469
      • Tamatinib
      • VX-702
    • T-Cell Co-Stimulation Modulator
      • RhuDex
    • Other Oral Therapies
      • 274150
      • CH-1504
      • CRx-102
      • K-832
      • PMI-001
      • R7277
  • Injectable Therapies
    • B-Cell Targeted Therapy
      • Atacicept
      • LymphoStat-B
      • TRU-015
    • Interleukin Inhibitors
      • AMG 108
    • Lymphotoxin Beta and LIGHT Pathway Inhibitor
      • Baminercept
    • RANK Ligand Inhibitor
      • Denosumab
    • TNF Inhibitor
      • tgAAC94
    • Other Injectable Therapies
      • MM-093
  • PHASEI PROJECTS
    • Kinase Inhibitors
      • ARRY-438162
      • ARRY-797
      • MLN0415
    • Anti-TNF
      • ART621
    • Others
      • PRTX-100
      • VAP-1
• APPENDIX 1: COMPETITOR RATIO ANALYSIS
• APPENDIX 2: COMPANY PROFILES
  • 4SC
  • Abbott
  • Amgen
  • Arana Therapeutics
  • AstraZeneca
  • Biogen Idec
  • Bristol-Myers Squibb
  • Can-Fite Biopharma
  • Chelsea Therapeutics
  • Chugai
  • CombinatoRx
  • Dainippon Sumitomo Pharma
  • Eisai
  • Eli Lilly
  • Genmab
  • GlaxoSmithKline
  • Human Genome Sciences
  • Johnson & Johnson
  • Kowa Pharmaceutical
  • Medarex
  • Medigene
  • Merck KGaA
  • Merrimack Pharmaceuticals
  • Millennium Pharmaceuticals
  • Mitsubishi Tanabe Pharma
  • Novartis
  • Phytomedics
  • Pozen
  • Pfizer
  • Rigel Pharmaceuticals
  • Roche
  • sanofi-aventis
  • Schering-Plough
  • Synta Pharmaceuticals
  • Takeda
  • Targeted Genetics
  • Toyama Chemical
  • Trubion
  • Wyeth
  • Vertex Pharmaceuticals
• APPENDIX 3: GLOSSARY
• APPENDIX 4: SOURCES
• APPENDIX 5: PRODUCT INDEX

INDEX OF TABLES

• Traditional DMARDs used in the treatment of RA
• ACR responses
• Products In Development For The Treatment Of Rheumatoid Arthritis
• Competitor Ratio Analysis Scores
• Six- and 12-month ACR responses for RAPID 1
• Six and 12 month mean mTSS changes from baseline for RAPID 1
• Competitor Ratio Analysis Scores
• Competitor Ratio Analysis Summary

INDEX OF CHARTS

• Synovitis And Joint Destruction In Rheumatoid Arthritis
• Bone Erosion In Untreated Rheumatoid Arthritis
• Current Views On The Pathogenesis Of Rheumatoid Arthritis
• Guidelines For The Management Of Rheumatoid Arthritis
• Global Rheumatoid Arthritis Drug Sales (2007E)
• Rheumatoid Arthritis Market (2007E-2015E)
• Global Market Share of Major Biologic RA Products (2007E)
• Global Market Share Of RA Biologics And Oral Therapies By Sales (2015E)
• Celebrex RA Sales (2008E-2015E)
• Remicade RA Sales (2008E-2015E)
• Humira RA Sales (2008E-2015E)
• Enbrel RA Sales (2008E-2015E)
• Kineret RA Sales (2008E-2015E)
• Rituxan/MabThera RA Sales (2008E-2015E)
• Orencia RA Sales (2008E-2015E)
• Launch Of Biologics In Late-Phase Development To Treat Rheumatoid Arthritis
• Cimzia RA Sales (2008E-2015E)
• Golimumab RA Sales (2009E-2015E)
• The Role Of IL-6 In Inflammation
• Actemra RA Sales (2008E-2015E)
• Ocrelizumab RA sales (2011E-2015E)
• Ofatumumab RA Sales (2010E-2015E)
• CF101 RA Sales (2012E-2015E)
• SC12267 RA Sales (2011E-2015E)
• CP-195543 RA Sales (2012E-2015E)
• CP-690550 RA Sales (2011E-2015E)
• Scio-469 RA Sales (2012E-2015E)
• R788 RA Sales (2011E-2015E)
• RhuDex RA Sales (2012E-2015E)
• Atacicept RA Sales (2011E-2015E)
• LymphoStat-B RA sales (2011E-2015E)
• TRU-015 RA Sales (2011E-2015E)
• AMG 108 RA Sales (2011E-2015E)
• Baminercept RA Sales (2010E-2015E)
• Denosumab RA Sales (2009E-2015E)